Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.
about
Bevacizumab for glioblastomaDevelopment and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
P2860
Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@en
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@nl
type
label
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@en
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@nl
prefLabel
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@en
Patient outcome in the Belgian ...... ab for recurrent glioblastoma.
@nl
P2093
P2860
P50
P1433
P1476
Patient outcome in the Belgian ...... mab for recurrent glioblastoma
@en
P2093
Barbara Stragier
Bertrand Filleul
Chantal Andre
Eric Joosens
Frank Bouttens
Frank Van Fraeyenhove
Jean-Francois Baurain
Lionel D'hondt
Paul M Clement
Philippe Vroman
P2860
P2888
P304
P356
10.1007/S00415-014-7633-Z
P577
2015-01-09T00:00:00Z